OTTAWA –
Health Canada has authorized an up to date model of Moderna’s COVID-19 booster vaccine.
The new bivalent shot targets the Omicron BA.4/BA.5 subvariants and is supposed for use as a booster dose for these aged 18 years and older.
It comes two months after Health Canada authorized a bivalent booster from Moderna that focused the Omicron BA.1 subvariant and the unique pressure.
Health Canada says a bivalent booster triggers “a powerful immune response” towards each of the more moderen Omicron subvariants, in addition to the unique SARS-CoV-2 virus strains.
The National Advisory Committee on Immunization says Omicron BA.4 and BA.5 are the dominant strains in circulation.
They function a number of key mutations from the unique SARS-CoV-2 virus, main NACI to strongly suggest bivalent boosters that concentrate on Omicron.
On Oct. 7, Health Canada authorized the Pfizer-BioNTech’s bivalent booster for folks aged 12 and older. It additionally targets the Omicron BA.4 and BA.5 subvariants.
This report by The Canadian Press was first printed Nov. 3, 2022.